FDA Approves KERENDIA to Treat Chronic Kidney Disease Associated with Type 1 Diabetes in Adults
The U.S. Food and Drug Administration has approved KERENDIA (finerenone) for adults with chronic kidney disease associated with type 1 diabetes.
CDC Merges Flu and COVID Divisions
The Centers for Disease Control and Prevention is merging its Influenza Division with the Coronavirus and Other Respiratory Diseases Division to create the Influenza and Respiratory Viruses Division.
CDC Issues Recommendations for 2026-2027 Influenza Vaccines
The Centers for Disease Control and Prevention has issues its recommendations for use of the seasonal 2026-2027 influenza (flu) vaccines.
FDA Approves Lisraya to Treat Dermatomyositis
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets to treat dermatomyositis in adults.
New COVID Vaccines Approved by FDA
Updated COVID-19 vaccines from Moderna, Novavax-Sanofi and Pfizer-BioNTech have been approved by the U.S. Food and Drug Administration.
FDA Approves First Freeze-Dried Plasma Product
The U.S. Food and Drug Administration has licensed Ezplaz Freeze Dried Plasma (FDP), the first freeze-dried plasma product licensed for use in the U.S.
Cancer Vaccine Plus KEYTRUDA Study Shows Positive Results in Treating Melanoma
A Phase III trial evaluating adjuvant treatment with intismeran autogene in combination with KEYTRUDA (pembrolizumab) showed positive results in treating patients with completely resected stage IIB-IV melanoma.
FDA Approves Takeda’s Orzeyful to Treat Type 1 Narcolepsy
The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults.
Infants More Susceptible Than Older Children to Severe Illness from Viruses
A new study has found infants are far more vulnerable than older children to severe illness from viruses such as influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2.
FDA Approves First mRNA Influenza Vaccine
The U.S. Food and Drug Administration has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.